Related Experiment Video
Updated: Feb 9, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
[Update on heart failure]
J Wintrich1, I Kindermann2, M Böhm2
1Klinik für Innere Medizin III - Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrbergerstraße, 66421, Homburg/Saar, Deutschland. Jan.Wintrich@uks.eu.
Insights
Heart failure management is crucial due to rising prevalence. Recent advances, including neprilysin inhibition, improve outcomes, but guideline-conform treatment remains vital for patients with heart failure.
Area of Science:
- Cardiology
- Internal Medicine
- Pharmacology
Background:
- Heart failure is a leading global disease, with increasing incidence due to aging populations.
- It is the most frequent diagnosis in hospitalized patients in Germany, despite recent mortality reductions.
- High mortality and morbidity rates necessitate guideline-conform treatment.
Purpose of the Study:
- To review current scientific knowledge on heart failure (2017-2018) based on European Society of Cardiology guidelines.
- To present new findings on heart failure with mid-range ejection fraction limitations.
- To discuss innovative diagnostic and therapeutic strategies, pharmacological developments, and comorbidity management.
Main Methods:
- Literature review of scientific knowledge from 2017-2018.
- Focus on European Society of Cardiology guidelines for heart failure management.
- Synthesis of information on diagnosis, therapy, and comorbidities.
Main Results:
- Highlights recent advancements in heart failure treatment, including neprilysin inhibition.
- Introduces new aspects of heart failure with mid-range ejection fraction.
- Discusses innovative diagnostic tools and therapeutic approaches.
Conclusions:
- Guideline-conform treatment is essential for managing heart failure.
- New pharmacological options offer improved outcomes but do not eliminate risks.
- Comprehensive management addressing comorbidities is key for heart failure patients.
Abstract:
Heart failure is one of the leading diseases in internal medicine worldwide. Because of the increase in population aging, the incidence and prevalence of heart insufficiency is rising annually and is now the most frequent individual diagnosis among hospitalized patients in Germany. The mortality rate has recently been reduced, since new pharmacological options, especially the inhibition of neprilysin, have been developed; however, heart failure is still associated with a high mortality and morbidity rate. Thus, guideline-conform treatment is of crucial importance. This review highlights and summarizes the current scientific knowledge on heart failure from 2017 and 2018 based on the guidelines of the European Society of Cardiology. New aspects about heart failure with middle grade limitations of ejection fraction are firstly presented. Subsequently, innovative diagnostic and therapeutic strategies, new pharmacological developments and handling of frequent comorbidities in patients with heart failure are discussed.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Diuretics
Heart Failure V: Medical Management

